Driving innovation
in inflammation and fibrosis
LATEST NEWS
About us
Laurent Pharma is a late stage clinical biotech company focusing on developing treatments for complex conditions caused by an unbalanced immune-inflammatory response.
![](https://laurentpharma.com/wp-content/uploads/2021/09/img_home_01-768x433.jpg)
![](https://laurentpharma.com/wp-content/uploads/2021/09/img_home_02-768x433.jpg)
Science
Targeting cell membrane lipid composition and fluidity as a new paradigm for regulating host defense and the inflammation process.
Pipeline
Laurent Pharma has completed two Phase 2 clinical studies with LAU-7b, a first-in-class proresolving drug candidate, in cystic fibrosis and COVID-19.
![](https://laurentpharma.com/wp-content/uploads/2021/09/img_home_04-768x433.jpg)
![](https://laurentpharma.com/wp-content/uploads/elementor/thumbs/lp_pill_02-pdu28xr8ans02114ocytcntfd5g3ggy55kzu6a1qtc.png)
LAU-7b is an oral drug candidate that showed potential to regulate membrane lipids and exert antiviral, inflammation-controlling, and antifibrotic properties.
News & Events
Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 3-6, 2024, San Diego, CA, USA
![](https://laurentpharma.com/wp-content/uploads/elementor/thumbs/img_news_home_06-px5ic7udj3cwflcfo9b7yrvyhkgfrgvq8vxbttit64.jpg)